FDA Reprimands Gilead Over Letairis Statements

Law360, New York (March 9, 2009, 12:00 AM EDT) -- The U.S. Food and Drug Administration has chastised Gilead Sciences Inc. for a sales representative's “false and misleading” statements that misbranded the hypertension drug Letairis and minimized “serious risks” associated with the medication.

In a letter to Gilead posted Thursday to its Web site, the FDA targeted statements made by the unnamed sales representative at a June 2008 international pulmonary hypertension conference in Houston.

Among other things, the agency said the representative stated that a risk management plan for Letairis issued by the FDA was “not...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.